How Dual Agonists Work
Dual agonists work on two appetite-regulating hormones simultaneously — GIP and GLP-1. The combination is not merely additive: the two signals interact synergistically, producing greater weight loss than either alone.
Quick read · 4 min
GLP-1 alone vs dual agonist
Trial averages — individual results vary
What GIP is
GIP (glucose-dependent insulinotropic polypeptide) is another gut hormone released after eating. Like GLP-1, it was originally studied for its role in insulin secretion. More recently, researchers discovered that GIP receptors are also present in the brain, fat tissue, bone, and pancreas — and that activating them has significant effects on appetite and fat metabolism.
How the dual action works
Plain English:
Dual agonists work on two hunger-related signals in the brain instead of one. The second signal (GIP) also improves how the body handles fat and insulin — and because it doesn't trigger as much nausea as GLP-1 at high doses, the two can be combined at full strength. This is why dual agonists tend to produce greater weight loss than single GLP-1 drugs.
- •Reduces appetite via brain receptors
- •Slows gastric emptying
- •Stimulates insulin secretion
- •Suppresses glucagon
- +Additional appetite reduction via brain GIP receptors
- +Improves insulin sensitivity (not just secretion)
- +Enhances fat metabolism via fat cell GIP receptors
- +Mitigates GLP-1's GI side effects
Why GIP matters for tolerability
A key engineering insight behind tirzepatide: GIP activation is well-tolerated at high doses — it does not trigger significant nausea on its own. GLP-1 activation, by contrast, can cause nausea when pushed to high doses.
Tirzepatide is intentionally designed with higher potency at the GIP receptor than at GLP-1. By leading with GIP activation, the molecule can achieve high total receptor engagement (producing significant appetite suppression and weight loss) while limiting nausea compared to equivalent GLP-1 agonism alone. This biased design is part of why tirzepatide showed greater weight loss than semaglutide in a direct head-to-head trial.
What the evidence shows
In a head-to-head trial comparing tirzepatide to semaglutide 2.4mg over 72 weeks in 751 adults without diabetes, tirzepatide produced significantly greater weight loss — both in body weight and waist circumference. This is attributed to the synergistic dual mechanism. NEJM 2025 ↗
Common questions
Next step most people take
Based on clinical trials · No rankings · Every claim linked to source
Last reviewed: April 2026